MEMS Tech stock broke 2yr downtrend now heading up, page-3

looks like Im talking to myself

Little Corn where have you gone?


Whats interesting is that the last research report from Helmsec said that the key challenge for BCT was getting product acceptance or proof of product acceptance via getting actual sales and BCT have achieved that with several local sales and a few overseas in China and the US

http://bluechiip.com/wp-content/uploads/2014/04/140403_BCT_Helmsec-Research-Report-Final1.pdf

Long Term value of the company will be derived from actual sales and revenue achieved but for now my thinking is it should be priced alot higher given the potential and the fact that management are derisking the story
uccessful in converting meaningful sale orders in the
near to medium term, then it is reasonable to expect such momentum
to
continue as success breeds success. Under
such a scenario, BCT's valuation would be many multiples of its current share price. Alter
natively, should sales not be
forthcoming, then with its constrained cash balance, BCT would be forced to return to the equity markets to seek
additional funding. Such a raising would likely be undertaken at a discount to the already depressed share price,
causing
further dilution existing shareholders.
BCT's immediate challenge is to source a management team with the ability to turbo charge sales efforts and convert
orders. Whilst the pressure is on for the company to achieve this in the near term, we are
cautiously optimistic that BCT
will succeed given its strong core product. We see BCT as a significantly leveraged exposure to the growing medical
technology industry
with enormous potential upside
.